She currently directs multi-institutional clinical trials evaluating novel approaches to improved diagnosis of breast cancer and is the recipient of numerous honors and awards including Best Cancer Doctors (Newsweek), Castle Connolly Best Doctors for Cancer and Top Doctor, Jewish Woman International’s Ten Women to Watch, the prestigious fellowship in the American College of Radiology and the Society of Breast Imaging. Brem’s research and clinical interest includes Minimally Invasive Breast Biopsy as well as New Technologies for the Earlier Diagnosis of breast cancer focusing Whole Breast Ultrasound for women with dense breast tissue for improved breast cancer detection and risk assessment, Artificial Intelligence for breast cancer detection and Molecular Imaging of the Breast. Currently she is the Director of Breast Imaging and Interventional Center at the George Washington Medical Institution and Professor of Radiology. Brem was on the faulty at John Hopkins as the Director of Breast Imaging. Brem completed both her Diagnostic Radiology Residency and Breast Imaging Fellowship at the John Hopkins Medical Institutions. Brem completed her undergraduate studies at Brandeis University followed by medical school at Columbia University where she graduated with honors. Brem was named the Program Leader for Breast Cancer at the GW Cancer Center. Rachel Brem is the Director of Breast Imaging and Intervention at The George Washington University Medical Center, Professor of Radiology and the Vice Chairman of the Department of Radiology. ScreenPoint are the only people that combine deep understanding of the physics, knowledge of clinical workflow and deep learning AI techniques to improve accuracy and speed of detection. There are fewer and fewer radiologists specialising in reading mammograms at a time when breast cancer incidence is increasing worldwide. We built a superb team of scientists to develop a unique system, Transpara, a blend of classic physics and deep learning artificial intelligence, presented as a decision support tool to increase efficiency. ![]() I met Nico Karssemeijer from Nijmegen University in 2000 when he was giving a keynote lecture on parallel research.īoth of us wanted to help radiologists identify potential cancers faster and at an earlier stage and to increase the chances of more women surviving breast cancer. My colleagues and I developed a mathematical model of the passage of X-rays through female breast tissue, a fundamental step towards developing a system able to recognise potential tumours. So I decided to move away from robotics and concentrate on the analysis of breast scans.’ ![]() ![]() “I wanted to understand why the medical profession wasn’t able to do a better job of detecting breast cancers at an earlier stage when they were more treatable. We are lean, focused on producing optimum results with cost savings passed on to our customers.”Ĭo-Founder of ScreenPoint Medical, Sir Michael Brady, was known internationally for his ground-breaking work in robotic image analysis at the University of Oxford but the death of his mother in law from breast cancer, caused him to change direction: “But we always remember that our excellence in innovation must be matched by the way we run our business. “Transpara is now being used by radiologists in clinical practice, but this is only the beginning! We are constantly innovating and we will continue to help doctors to achieve higher breast cancer survival rates and at the same time, minimise patient distress and the cost of unnecessary treatments.” The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |